MedTrace Logo

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

NCT07406633 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-05-19

No results posted yet for this study

Summary

This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.

Conditions

  • GIST - Gastrointestinal Stromal Tumor
  • GIST
  • GIST Metastatic Cancer
  • Gastro Intestinal Stromal Tumour
  • Gastrointestinal Tumors

Interventions

DRUG

KQB198

Oral KQB198

DRUG

Imatinib (Gleevec)

Oral Imatinib

Sponsors & Collaborators

  • Kumquat Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-10-31
Completion
2028-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07406633 on ClinicalTrials.gov